Jan Torzewski

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9555616/publications.pdf

Version: 2024-02-01

55	2,647	279798	182427
papers	citations	23 h-index	51 g-index

63	63	63	3039
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Resorbable Magnesium Scaffold Magmaris in Acute Coronary Syndrome: An Appraisal of Evidence and User Group Guidance. Cardiovascular Revascularization Medicine, 2022, 39, 106-113.	0.8	5
2	Cardiac Glycosides Lower C-Reactive Protein Plasma Levels in Patients with Decompensated Heart Failure: Results from the Single-Center C-Reactive Protein-Digoxin Observational Study (C-DOS). Journal of Clinical Medicine, 2022, 11, 1762.	2.4	2
3	A Report on the First 7 Sequential Patients Treated Within the C-Reactive Protein Apheresis in COVID (CACOV) Registry. American Journal of Case Reports, 2022, 23, e935263.	0.8	9
4	Targeting C-Reactive Protein by Selective Apheresis in Humans: Pros and Cons. Journal of Clinical Medicine, 2022, 11, 1771.	2.4	12
5	‹scp›BIOSOLVEâ€IV‹/scp›â€registry: Safety and performance of the Magmaris scaffold: 12â€month outcomes of the first cohort of 1,075 patients. Catheterization and Cardiovascular Interventions, 2021, 98, E1-E8.	1.7	39
6	C-Reactive Protein Apheresis as Anti-inflammatory Therapy in Acute Myocardial Infarction: Results of the CAMI-1 Study. Frontiers in Cardiovascular Medicine, 2021, 8, 591714.	2.4	47
7	Successful Treatment of a 39-Year-Old COVID-19 Patient with Respiratory Failure by Selective C-Reactive Protein Apheresis. American Journal of Case Reports, 2021, 22, e932964.	0.8	11
8	TCT-117 Performance and Safety of the Resorbable Magnesium Scaffold, Magmaris, in a Real-World Setting: Primary and Secondary Endpoint Analysis of the Full Cohort (2,066 Subjects) of the BIOSOLVE-IV Registry. Journal of the American College of Cardiology, 2021, 78, B49.	2.8	1
9	No difference in 30-day outcome and quality of life in transradial versus transfemoral access â€“ Results from the German Austrian ABSORB registry (GABI-R). Cardiovascular Revascularization Medicine, 2021, , .	0.8	1
10	Two year efficacy and safety of small versus large ABSORB bioresorbable vascular scaffolds of â‰¤18Âmm device length: A subgroup analysis of the German-Austrian ABSORB RegIstRy (GABI-R). IJC Heart and Vasculature, 2020, 27, 100501.	1.1	0
11	First-in-Man: Case Report of Selective C-Reactive Protein Apheresis in a Patient with SARS-CoV-2 Infection. American Journal of Case Reports, 2020, 21, e925020.	0.8	25
12	Twelve-month outcomes of 400 patients treated with a resorbable metal scaffold: insights from the BIOSOLVE-IV registry. EuroIntervention, 2020, 15, e1383-e1386.	3.2	32
13	TCT-45 Safety and Performance of the Resorbable Magnesium Scaffold, Magmaris, in a Real-World Setting: First Cohort Subjects at 12-Month Follow-Up of the BIOSOLVE-IV Registry. Journal of the American College of Cardiology, 2019, 74, B45.	2.8	2
14	Selective Câ€Reactive Proteinâ€Apheresis in Patients. Therapeutic Apheresis and Dialysis, 2019, 23, 570-574.	0.9	29
15	500.01 Safety and Performance of the Resorbable Magnesium Scaffold, Magmaris in a Real-World Setting - 12-Month Follow-Up of First 600 Subjects in Biosolve-IV Registry. JACC: Cardiovascular Interventions, 2019, 12, S39.	2.9	2
16	â€œFirst in Manâ€• Case Report of Selective C-Reactive Protein Apheresis in a Patient with Acute ST Segment Elevation Myocardial Infarction. Case Reports in Cardiology, 2018, 2018, 1-4.	0.2	20
17	Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial. Lancet, The, 2018, 392, 1530-1540.	13.7	103
18	Inhibiting C-Reactive Protein Synthesis by Cardiac Glycosides in Humans. The Open Conference Proceedings Journal, 2016, 7, 7-11.	0.6	1

#	Article	IF	Citations
19	Large diverticulum of the urinary bladder: A rare cause of deep vein thrombosis with consecutive pulmonary embolism. Canadian Urological Association Journal, 2015, 9, 321.	0.6	1
20	C-Reactive Protein in Human Atherogenesis: Facts and Fiction. Mediators of Inflammation, 2014, 2014, 1-6.	3.0	31
21	C-Reactive Protein and Arteriosclerosis. Mediators of Inflammation, 2014, 2014, 1-1.	3.0	6
22	The Analysis of microRNA Expression Profiling for Coronary Artery Disease. Cardiology, 2014, 127, 62-69.	1.4	10
23	In-hospital results of transcatheter aortic valve implantation (TAVI) in a district hospital â€" An approach to treat TAVI patients in rural areas. International Journal of Cardiology, 2013, 168, 4845-4846.	1.7	5
24	Successful Use of mRNAâ€Nucleofection for Overexpression of Interleukinâ€10 in Murine Monocytes/Macrophages for Antiâ€inflammatory Therapy in a Murine Model of Autoimmune Myocarditis. Journal of the American Heart Association, 2012, 1, e003293.	3.7	30
25	Road Map to Drug Discovery and Developmentâ€"Inhibiting C-reactive protein for the Treatment of Cardiovascular Disease. Journal of Bioequivalence & Bioavailability, 2011, 01, .	0.1	4
26	Diagnostic performance of magnetic resonance first pass perfusion imaging is equally potent in female compared to male patients with coronary artery disease. Clinical Research in Cardiology, 2010, 99, 21-28.	3.3	20
27	Characterization of patients with acute chest pain using cardiac magnetic resonance imaging. Clinical Research in Cardiology Supplements, 2010, 5, 63-69.	2.0	2
28	Cardiac involvement in a female carrier of Duchenne muscular dystrophy. International Journal of Cardiology, 2010, 138, 302-305.	1.7	30
29	Cardiac glycosides potently inhibit C-reactive protein synthesis in human hepatocytes. Biochemical and Biophysical Research Communications, 2010, 394, 233-239.	2.1	16
30	Interferon Î²-1b Therapy in Chronic Viral Dilated Cardiomyopathyâ€"Is There a Role for Specific Therapy?. Journal of Cardiac Failure, 2010, 16, 348-356.	1.7	24
31	Potential Myogenic Stem Cell Populations: Sources, Plasticity, and Application for Cardiac Repair. Stem Cells and Development, 2009, 18, 813-830.	2.1	15
32	Electrocardiographic and cardiac magnetic resonance imaging parameters as predictors of a worse outcome in patients with idiopathic dilated cardiomyopathy. European Heart Journal, 2009, 30, 2011-2018.	2.2	87
33	Myocardial inflammation and non-ischaemic heart failure: is there a role for C-reactive protein?. Basic Research in Cardiology, 2009, 104, 591-599.	5.9	38
34	Prognostic significance of magnetic resonance imaging parameters in patients with idiopathic dilated cardiomyopathy. Journal of Cardiovascular Magnetic Resonance, 2009, 11, .	3.3	0
35	Characterization of patients with acute chest pain using cardiac magnetic resonance imaging. Clinical Research in Cardiology, 2008, 97, 760-767.	3.3	51
36	Câ€reactive protein specifically binds to FcÎ³ receptor typeâ€„I on a macrophageâ€like cell line. European Journal of Immunology, 2008, 38, 1414-1422.	2.9	31

#	Article	IF	Citations
37	Interleukin-1Î² stimulates acute phase response and C-reactive protein synthesis by inducing an NFÎºB- and C/EBPÎ²-dependent autocrine interleukin-6 loop. Molecular Immunology, 2008, 45, 2678-2689.	2.2	76
38	Interferon beta-1b Therapy in Patients Suffering from Dilated Cardiomyopathy and Chronic Virus Persistence â€“ No Benefit for Specific Therapy?. Journal of Cardiac Failure, 2008, 14, S97-S98.	1.7	0
39	C-Reactive Protein and Atherosclerosis: An Update. Vascular Disease Prevention, 2008, 5, 178-182.	0.2	0
40	C-Reactive Protein and Atherosclerosis: An Update. Vascular Disease Prevention, 2008, 5, 178-182.	0.2	2
41	Prognostic role of myocardial tumor necrosis factor-alpha and terminal complement complex expression in patients with dilated cardiomyopathy. European Journal of Heart Failure, 2007, 9, 51-54.	7.1	12
42	Affinity of C-Reactive Protein toward FcÎ³RI Is Strongly Enhanced by the Î³-Chain. American Journal of Pathology, 2007, 170, 755-763.	3.8	21
43	mRNAâ€Mediated Gene Delivery Into Human Progenitor Cells Promotes Highly Efficient Protein Expression. Journal of Cellular and Molecular Medicine, 2007, 11, 521-530.	3.6	48
44	Efficient transient genetic labeling of human CD34+progenitor cells forin vivoapplication. Regenerative Medicine, 2006, 1, 223-234.	1.7	7
45	Myocardial biopsy findings and gadolinium enhanced cardiovascular magnetic resonance in dilated cardiomyopathy. European Journal of Heart Failure, 2006, 8, 162-166.	7.1	34
46	Serum Starvation and Growth Factor Receptor Expression in Vascular Smooth Muscle Cells. Journal of Vascular Research, 2006, 43, 157-165.	1.4	16
47	Highly Efficient mRNA- and cDNA-Based Transient Gene Delivery into Human Progenitor Cells.. Blood, 2006, 108, 5471-5471.	1.4	0
48	Critical Role for Monocyte Chemoattractant Protein-1 and Macrophage Inflammatory Protein-1Î± in Induction of Experimental Autoimmune Myocarditis and Effective Antiâ€“Monocyte Chemoattractant Protein-1 Gene Therapy. Circulation, 2005, 112, 3400-3407.	1.6	139
49	Myocardial biopsy based classification and treatment in patients with dilated cardiomyopathy. International Journal of Cardiology, 2005, 104, 92-100.	1.7	45
50	C-Reactive Protein and Atherogenesis. American Journal of Pathology, 2005, 167, 923-925.	3.8	37
51	Ultrasensitive Confocal Fluorescence Microscopy of C-Reactive Protein Interacting With FcÎ³RIIa. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 2372-2377.	2.4	53
52	C-Reactive Proteinâ€“Mediated Low Density Lipoprotein Uptake by Macrophages. Circulation, 2001, 103, 1194-1197.	1.6	762
53	C-Reactive Protein Frequently Colocalizes With the Terminal Complement Complex in the Intima of Early Atherosclerotic Lesions of Human Coronary Arteries. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1386-1392.	2.4	494
54	Immunohistochemical Colocalization of the Terminal Complex of Human Complement and Smooth Muscle Cell Î±-Actin in Early Atherosclerotic Lesions. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 2448-2452.	2.4	61

#	Article	IF	Citations
55	Complement-Induced Release of Monocyte Chemotactic Protein-1 From Human Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 673-677.	2.4	93